var data={"title":"Ioxaglate meglumine and ioxaglate sodium: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ioxaglate meglumine and ioxaglate sodium: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6395?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ioxaglate-meglumine-and-ioxaglate-sodium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ioxaglate meglumine and ioxaglate sodium: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26524994\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Not for intrathecal use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184042\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hexabrix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858410\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Hexabrix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184045\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iodinated Contrast Media;</li>\n      <li>\n        Radiological/Contrast Media (Ionic, Low Osmolality)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24538485\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective coronary arteriography (with or without left ventriculography): Intra-arterial:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Left coronary arteriography: Usual dose: 8 mL (range 2 to 14 mL); may repeat as needed to a total dose of 150 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Right coronary arteriography: Usual dose: 5 mL (range: 1 to 10 mL); may repeat as needed to a total dose of 150 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Left ventriculography: Usual dose (single injection): 45 mL (range: 35 to 45 mL); may repeat as necessary to a maximum dose (for selective coronary arteriography and left ventriculography) of 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral arteriography: Intra-arterial: Total procedural dose should not exceed 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aorto-iliac runoff studies (single dose): 45 mL (range: 20 to 80 mL); may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Common iliac, external iliac, femoral arteries (single dose): 30 mL (range: 10 to 50 mL); may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Upper limb (single dose):  20 mL (range: 15 to 30 mL); may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aortography and selective visceral arteriography: Intra-arterial: Total dose should not exceed 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aorta: 25 to 50 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Celiac artery: 40 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inferior mesenteric artery: 8 to 15 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Superior mesenteric artery: 20 to 40 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cerebral angiography: Intra-arterial: Total dose per procedure should not exceed 150 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Common carotid artery: 9 mL (range: 6 to 12 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vertebral arteries: 8 mL (range: 5 to 12 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aortic arch injections (4 vessel studies) in conjunction with cerebral angiography: Usual dose: 40 mL (range: 30 to 50 mL) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intra-arterial digital subtraction angiography (volume and concentration used is typically ~50% or less than volume used for conventional procedures; dose and flow rate varies depending on selectivity of injection site and area being examined; use a 1:1 dilution, with sterile water for injection): Intra-arterial: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Carotid arteries: 6 to 10 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vertebral arteries: 4 to 8 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aorta: 25 to 50 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subclavian or brachial arteries: 2 to 10 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Major branches of abdominal aorta: 2 to 20 mL; may repeat as necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravenous digital subtraction angiography: IV: Usual dose 30 to 50 mL (depending on area being imaged); may repeat as necessary; total procedural dose should not exceed 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral venography (phlebography): IV:  Usual dose: 50 to 100 mL (undiluted) as a single rapid injection; dose varies based on patient size and condition, and technique used.  May also use reduced concentrations (reduced to a 20% concentration); the usual dose of diluted contrast media ranges from 75 to 150 mL per extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretory urography: IV:  Usual dose: 50 to 75 mL (0.7 to 1 mL/kg); higher doses of 100 to 150 mL (1.5 to 2 mL/kg) may be indicated if poor visualization is anticipated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhancement of computed tomographic head imaging: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &le;68.2 kg (150 lbs): Usual dose: 2 mL/kg (0.9 mL/lb)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &gt;68.2 kg (150 lbs): Usual dose: 135 mL; not to exceed 150 mL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhancement of computed tomographic body imaging (dose depends on area to be examined): IV: 30 to 150 mL (0.9 to 2 mL/kg [0.4 to 0.9 mL/lb]); for prolonged enhancement, may require 25 to 50 mL as a rapid bolus followed by an infusion of 100 to 125 mL  (total dose not to exceed 150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arthrography (amount of contrast depends on the size of the joint and technique used): Intra-articular: <b>Note:</b> Lower volumes are generally used for double-contrast examinations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Knee, hip: 5 to 15 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Shoulder, ankle: 5 to 20 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Temporomandibular: 0.5 to 0.7 mL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hysterosalpingography (amount of contrast depends on anatomic variations and/or disease process): Intrauterine: Usual dose: 5 to 15 mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24538318\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric angiocardiography: Catheter injection into heart or associated large vessels: Usual total dose per procedure (including diagnostic and test dose) is ~4 mL/kg (range 1.5 to 5 mL/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Young Children: 1.5 mL/kg (range: 1 to 2 mL/kg); may use small test volumes of ~2 mL to test catheter placement</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Older Children: 30 to 45 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretory urography: IV:  Total dose should not exceed 5 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants under 6 months: 3 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants over 6 months and Children: 2 mL/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962290\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in advanced impairment and in setting of combined renal and hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962291\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184034\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, Solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hexabrix: Ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (20 mL, 50 mL, 100 mL, 150 mL, 200 mL) [provides organically-bound iodine 32% (320 mg/mL); contains edetate calcium disodium, sodium 3.48 mg (0.15 mEq)/mL]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184030\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674563\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast media should be at or close to body temperature when injected. Patients should omit the meal that precedes the examination. Appropriate premedication (may include a barbiturate, tranquilizer, or an analgesic) may be administered prior to the examination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric angiocardiography: Administer via catheter as a rapid injection over 1 to 2 seconds into a chamber of the heart or associated large blood vessel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral arteriography: Peripheral arteriography is usually performed with local anesthesia; it rarely requires general anesthesia. Fluoroscopy is recommended to avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cerebral angiography: Cerebral angiography is usually performed with local or general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intra-arterial digital subtraction angiography: Patient should be well hydrated prior to procedure. Inject at a flow rate approximately equal to the flow rate of the vessel injected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravenous digital subtraction angiography: Patient should be well hydrated prior to procedure. Inject centrally into either the superior or inferior vena cava, or right atrium, or peripherally into an arm vein. For peripheral injections, use a catheter length of ~20 cm to reduce risk of extravasation. Injection rate will vary based on catheter site placement. Central catheter injections are generally at a rate of 10 to 30 mL/second; peripheral injections are generally at a rate of 12 to 20 mL/second. If using arm vein, flush with 20 to 25 mL D<sub>5</sub>W or NS immediately following contrast media injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhancement of computed tomographic head imaging: Patient should be well hydrated prior to procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Contrast enhancement of computed tomographic body imaging: Patient should be well hydrated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral venography (phlebography): Injection or infusion into vein in upper or lower extremity. Fluoroscopy is recommended to avoid extravasation. Following the procedure, flush with D<sub>5</sub>W or NS; may also massage and elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretory urography: Unless contraindicated, a low residue diet the day preceding the exam and a laxative the evening prior to exam may be given. Do not fluid restrict for infants and small children. The total dose is injected over 30 to 90 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arthrography: Concomitant epinephrine is not needed due to the low osmolality (rate of contrast media absorption is reduced). Local anesthesia is usually necessary. Passive or active manipulation is used to disperse medium throughout the joint.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hysterosalpingography: Perform exam 8 to 10 days after onset of menses. Patient should empty bladder prior to exam. Administer slowly under fluoroscopic control, do not use undue pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>not</b> flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Zenk 1981) <b>or</b> injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184035\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Imaging:</b> Pediatric angiocardiography; selective coronary arteriography (with or without left ventriculography); peripheral arteriography; aortography and selective visceral arteriography; cerebral angiography; intra-arterial digital subtraction angiography; intravenous digital subtraction angiography; peripheral venography (phlebography); excretory urography; contrast enhancement of computed tomographic head and body imaging; arthrography; hysterosalpingography.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174554\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24793965\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Frequencies not defined; reactions may vary with procedure. Some reactions listed are based on reports for other agents in this same pharmacologic class, and may not be specifically reported for ioxaglate meglumine and ioxaglate sodium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Altered blood pressure (transient [cerebral angiography]), angina pectoris (selective coronary arteriography), cardiac arrest, cardiac arrhythmia, cardiac decompensation, cardiac fibrillation, cerebrovascular accident (cerebral angiography), coronary insufficiency, facial edema, facial flushing, flushing, hypotension, hypotensive shock, ischemic heart disease, myocardial infarction, peripheral edema, shock (selective coronary arteriography), syncope, thrombophlebitis, thrombosis, vasodilatation, venospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Amnesia (cerebral angiography), aphasia, brachial plexus injury (peripheral arteriography), burning sensation (cerebral angiography), chills, coma, confusion (cerebral angiography), convulsions, disorientation (with hallucination [cerebral angiography]), dizziness, flushing sensation, headache, hyperthermia, neurologic abnormality (reversible [cerebral angiography]), paralysis (resulting from spinal cord injury), paresis, transverse myelitis, visual hallucination (transient [cerebral angiography])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acute generalized exanthematous pustulosis, erythema, maculopapular rash, pruritus, skin discoloration, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Altered thyroid hormone levels (transient suppression; premature infants and infants with underlying medical conditions may be more vulnerable), hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps (hysterosalpingography), abdominal pain (hysterosalpingography), abdominal tenderness (hysterosalpingography), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, angioedema, hypersensitivity reaction (including chest tightness, choking sensation, diaphoresis, and xerostomia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: DRESS syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Arterial thrombosis at injection site (peripheral arteriography), bleeding at injection site (peripheral arteriography), pain at injection site, warm sensation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (arthrography), laryngospasm, muscle spasm, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctival abnormalities, vision loss (sometimes lasting 1 week [cerebral angiography]), visual field defect (cerebral angiography), visual field loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal disease, renal failure (temporary)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, asthma, bronchospasm, cough, cyanosis, dyspnea, nasal congestion, pulmonary edema, sneezing, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (hysterosalpingography)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184037\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ioxaglate or any component of the formulation; use in myelography; hysterosalpingography should not be performed during the menstrual period, in pregnant women, in patients with known genital tract infection, or in whom cervical conization or curettage has been performed within 30 days; arthrography should not be performed with infection present in or near the joint.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24537561\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media reactions: Adverse reactions (including delayed reactions) have occurred, including serious and life-threatening reactions. Most cases are minor; however, serious and life-threatening reactions may occur without warning and often resemble allergic-type reactions. Obtain allergy and hypersensitivity history prior to administration. Patients with a history of bronchial asthma, allergy (including food allergy), family history of allergy, or prior allergy or hypersensitivity to contrast agents are at a higher risk for allergic reaction. Pretesting for allergic reaction may not reliably predict potential for reaction. Premedication with antihistamines or corticosteroids should be considered in patient at risk for allergic reaction (strong allergy history, prior contrast media reaction, or positive pretest) to reduce the incidence and severity of reactions. Begin corticosteroids early prior to contrast media and continue for 24 hours after administration. Administer antihistamines within 30 minutes before contrast agent. Monitor closely for 30 to 60 minutes after administration of the contrast media and discontinue immediately if a serious reaction occurs. A higher incidence of adverse reactions was reported in patients also receiving general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to iothalamate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endotoxemia: Contrast media studies should be undertaken with caution in patients with endotoxemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid infiltration. Ioxaglate meglumine and ioxaglate sodium is hypertonic. Burning pain, hematomas, bruising, thrombophlebitis, and tissue necrosis have been reported with extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthermia: Contrast media studies should be undertaken with caution in patients with elevated body temperatures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media have occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule. Iodine-containing contrast agents may alter results of thyroid function tests that are dependent on iodine estimation and may affect results of radioiodine uptake studies; perform these studies prior to diagnostic tests with iodinated contrast media.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants); some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Serious neurologic sequelae, including paralysis (permanent) may occur following cerebral arteriography, selective spinal arteriography, and arteriography of vessels supplying the spinal cord. Do not inject contrast media after administration of vasopressors; may potentiate neurologic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: Acute renal failure has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent, and in diabetic patients with diabetic nephropathy, susceptible nondiabetic patients (eg, elderly patients with preexisting renal disease), and patients with occult renal disease (particularly patients with diabetes and/or hypertension); avoid fluid restriction and maintain normal hydration in these patients. Preparatory dehydration may contribute to acute renal failure in infants, young children and elderly patients, patients with preexisting renal impairment, multiple myeloma, advanced vascular disease, and diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Serious, rarely fatal thromboembolic events causing MI and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Use meticulous intravascular administration techniques during angiographic procedures. Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with combined renal and hepatic impairment; excretion may be impaired.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in patients with multiple myeloma; use of intravascular contrast agents may lead to irreversible progressive anuria, renal impairment, and death. Dehydration may be a causative factor; partial dehydration in preparation for procedures may precipitate myeloma protein in renal tubules and is not recommended in myeloma patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Minimize the amount of contrast agent used (for intravascular administration) and monitor blood pressure throughout procedure. Therapy to manage hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with advanced renal disease. Excretion may be impaired; use only if clearly needed. Patients with combined renal and hepatic disease, severe hypertension or heart failure, and recent renal transplant are at increased risk for impaired excretion. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in homozygous sickle cell patients; administration of contrast media may result in disease exacerbation. Fluid restriction is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Subarachnoid hemorrhage: In patients with subarachnoid hemorrhage, contrast administration may be associated with deterioration in clinical status (including seizure and fatality); administer with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Preparatory dehydration may contribute to acute renal failure in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Preparatory dehydration may contribute to acute renal failure in infants and young children. Infants are more likely to respond with seizures than adults; the amount of total dosage is particularly important. In infants &lt;7 kg, repeated injections are considered hazardous (especially in infants with preexisting compromised right heart function or obliterated pulmonary vascular beds).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Not for intrathecal use.</b> Serious adverse reactions (including death, seizure, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema) have been reported with inadvertent intrathecal administration of iodinated contrast agents not indicated for the intrathecal route. In contrast-enhanced computerized tomography, contrast may obscure some lesions previously seen on unenhanced CT scans.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Health care providers using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24574350\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24574347\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8969&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184032\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184039\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Hysterosalpingography is contraindicated in pregnant patients. In general, iodinated contrast media agents may cross the placenta; use should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184040\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ioxaglate salts are present in breast milk. Because of the potential for serious adverse reactions in the breastfeeding infant, bottle feedings are recommended by the manufacturer for 24 hours after administration. Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant's GI tract, other sources note breastfeeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9732468\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674648\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function, blood pressure, hydration; monitor for extravasation during IV administration; monitor for hypersensitivity reactions for &ge;30 to 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric angiocardiography: Monitor ECG and vital signs throughout procedure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral arteriography/intra-arterial (brachial) injections: Monitor blood pressure for ~10 minutes after injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">During administration of large doses, continuously monitor vital signs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24538041\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radiopaque contrast agent; opacifies vessels in the path of the flow of the contrast medium, permitting radiographic visualization of the internal structures of the body.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24538043\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Rapid (following intravascular administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 92 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IV: 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily and as unchanged drug); feces (minor)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24145317\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hexabrix Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">39.3-19.6% (20 mL): $39.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038662\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Hexabrix (AR, AT, AU, BE, CH, CL, CZ, DE, DK, EG, ES, FI, FR, GB, GR, HN, IE, IT, KR, LB, LU, NL, NO, NZ, PT, PY, QA, SE, SG, SI, TH, TR, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioxaglate-meglumine-and-ioxaglate-sodium-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hexabrix (Ioxaglate meglumine and ioxaglate sodium) [prescribing information]. Princeton, NJ: Guerbet LLC; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Iodine-containing contrast agents for medical imaging. Food and Drug Administration website. Available at <a href=\"http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm\" target=\"_blank\">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm</a>. Updated November 17, 2015. Accessed November 18, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jneid H, Anderson JL, Wright RS, et al, &quot;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>Circulation</i>, 2012, 126(7):875-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioxaglate-meglumine-and-ioxaglate-sodium-drug-information/abstract-text/22800849/pubmed\" target=\"_blank\" id=\"22800849\">22800849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein LW, Sheldon MW, Brinker J, et al, &quot;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&quot; <i>Catheter Cardiovasc Interv</i>, 2009, 74(4):728-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioxaglate-meglumine-and-ioxaglate-sodium-drug-information/abstract-text/19830793/pubmed\" target=\"_blank\" id=\"19830793\">19830793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laskey WK, Jenkins C, Selzer F, et al, &quot;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&quot; <i>J Am Coll Cardiol</i>, 2007, 50(7):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioxaglate-meglumine-and-ioxaglate-sodium-drug-information/abstract-text/17692741/pubmed\" target=\"_blank\" id=\"17692741\">17692741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &quot;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&quot; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioxaglate-meglumine-and-ioxaglate-sodium-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioxaglate-meglumine-and-ioxaglate-sodium-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-2102.e3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ioxaglate-meglumine-and-ioxaglate-sodium-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8969 Version 92.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F26524994\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F184042\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F20858410\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F184045\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F24538485\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F24538318\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15962290\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962291\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184034\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F184030\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24674563\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F184035\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174554\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F24793965\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184037\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F24537561\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F24574350\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F24574347\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184032\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F184039\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F184040\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9732468\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24674648\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F24538041\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F24538043\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F24145317\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038662\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8969|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ioxaglate-meglumine-and-ioxaglate-sodium-patient-drug-information\" class=\"drug drug_patient\">Ioxaglate meglumine and ioxaglate sodium: Patient drug information</a></li></ul></div></div>","javascript":null}